Intraocular Tumor Ultrasound Differentiation Handheld Ophthalmic Probe

An intraocular tumor is a growth inside the eye. Most arise in the choroid, the dense bed of blood vessels that lines the back of the eye behind the retina. The commonest one in adults is a melanoma, a dark pigmented tumor that can spread to the rest of the body if it is left alone. Some growths are harmless, a flat freckle that never changes. The whole task is to tell one kind from another. Ultrasound is the tool that shows a tumor through the eye and measures it. A handheld probe shows the mass, its shape, and the tissue it is made of, on an eye a light cannot always reach. Ocular melanoma is the most common cancer to start inside the adult eye.

A growth inside the eye

A tumor in the eye announces itself in several ways. Some are found by chance, on a routine eye exam, a dome the optician spots at the back of a quiet eye. Some announce themselves with lost sight, a shadow in the vision where the growth has lifted the retina off the wall. Some hide behind a bleed or a cataract, an eye that cannot be seen into at all. A patient with a known cancer elsewhere is watched for a growth that has travelled to the eye. Each of these brings the same question to the clinic: what is the mass, and is it dangerous. The growth can press on the macula and blur the centre of sight. It can throw off floaters and flashes by tugging on the retina. It can also sit silent for years, found only when an optician looks in.

The eye is one of the few places a tumor can be watched directly. A growth on the skin is biopsied without a thought. A growth in the eye is harder to reach. A needle into it carries its own risk. So the eye leans on imaging more than most organs do. Ultrasound carries much of that load. It takes the size of a mass, its shape, and the kind of tissue inside it. It does so over and over without harm. A tumor is measured one month and measured again the next, the scan watching for the growth that marks a dangerous one. Each scan is quick, a painless few minutes over a closed lid. The same tumor can be followed for years this way, a row of measurements building a record no single look could give. That record is often what tells a freckle from a slow melanoma.

The choroid is where most of the trouble starts. It is a layer packed with the pigment cells that can turn into a melanoma and with the vessels that can grow a hemangioma. A cancer from the breast or the lung can seed it from the bloodstream. The retina in front of it grows its own childhood tumor, the retinoblastoma. Each of these raises a mass off the back wall of the eye. Each has its own look on the scan. That look is how the scan begins to name the growth. The iris and the ciliary body at the front can grow a melanoma too. Most start further back in the choroid. The choroid’s rich blood supply is also what lets a melanoma there spread to the liver if it is left alone.

A solid mass on the scan

A tumor shows as a solid mass on the B-scan, a mound of tissue rising off the wall into the dark of the vitreous. It has body and substance, a filled shape with its own thickness. The scan draws its outline against the black cavity, a dome sitting on the inner wall of the eye. A trained eye knows a solid growth from a flat membrane in the first sweep. The B-scan is the wide view, the whole back of the eye on one screen. The mass shows as a clear, raised shape against the empty dark of the vitreous. Its edges, its height, and its inner shade all come off that one picture.

The shape of the mound carries meaning. Most tumors rise as a smooth, low dome, a gentle hill on the wall. A choroidal melanoma can grow into a mushroom, a narrow stalk swelling into a broad head, when it breaks through the thin membrane that holds the choroid in. That collar-button shape is close to a signature of a melanoma. A lumpy, irregular surface, a mass with more than one head, points toward a cancer that has spread to the eye from somewhere else. The mushroom forms when the tumor punches through Bruch’s membrane, the thin sheet under the retina, and mushrooms out into the eye. Not every melanoma takes that shape. A smooth dome is the commoner look. The shape narrows the guess. It does not settle it.

The size of the mass is taken off the scan in two measurements. The base is how wide the tumor sits on the wall. The height is how far it stands up from the wall into the eye. A small flat lesion, only a millimetre or two high, is most often a harmless freckle. Anything taller, especially anything that has gained height since it was last seen, gets watched with far more care. The base and the height together place a growth on the line between watching and treating. The base is taken in millimetres across the wall, the height in millimetres off it. A choroidal melanoma is often more than two millimetres tall when it first raises concern. Both numbers are written down and kept for every visit that follows.

The mass also tells how it has disturbed the eye around it. A growing tumor lifts the retina off the wall at its edges, a detachment the scan shows running away from the mound. Fluid can gather under the retina downhill from the growth. The vitreous over a tumor can fill with cells the growth has shed. The scan shows the mass and its wake in the same sweep, building the fuller picture the question needs. A tumor that leaks fluid lifts a wider detachment than its own footprint, the retina floating off well past the mound. Cells shed into the vitreous can cloud the view in their own right. The scan sorts the solid mass from the loose fluid and the floating cells around it.

Telling one tumor from another

The picture so far names a mass. Naming the kind of mass takes a closer look. The A-scan is the tool for it. The A-scan runs a single line of sound through the tumor and plots the strength of every echo along it as a row of spikes. The height of those spikes inside the tumor is what separates one growth from another. The denser and busier the tissue, the taller and more crowded the spikes it sends back. That inner pattern is a fingerprint of the tissue. The A-scan shows as a tracing of peaks, the height of each one set by the echo at that depth. Inside a tumor the peaks rise and fall by how tightly the cells are packed. A reader learns to judge that height by eye against a known scale.

A choroidal melanoma has a quiet inside. The A-scan spikes inside it are low. They hold the same low height clear across the mass. This is the sign called low internal reflectivity, the mark of a tumor built of dense, regular cells. On the B-scan that same quiet shows as a dark, hollow-looking zone within the dome, an acoustic emptiness under the bright surface. The melanoma also scoops out the choroid beneath it and casts a soft shadow into the orbit behind. Low reflectivity, a dome or mushroom shape, and that scooped-out base are the three signs that point hardest at a melanoma. The hollow inside a melanoma comes from its dense, even cells, all reflecting the sound the same low way. The shadow it throws lets the sound pass into the orbit behind, where a soft dark wedge appears. Taken together, those signs raise a melanoma to the top of the list.

The other growths show their own way. A choroidal nevus, the harmless freckle, is small, a thin flat patch that barely lifts off the wall. A metastasis, a cancer spread from the body, often sits as a lumpy mound with a bright, busy inside, high internal reflectivity. It can show in both eyes at once. A choroidal hemangioma, a benign tangle of vessels, shines brightly all the way through, top to bottom. Each pattern is a different tissue seen through the same probe. A nevus is watched until it shows a reason to worry. A metastasis sends the search back to the body, often to a breast or a lung cancer already known. A hemangioma can pair with a birthmark on the face in a condition present from birth. Each growth comes with its own set of clues beyond the scan.

A child’s eye carries its own tumor. A retinoblastoma grows on the retina in the first years of life. It packs flecks of calcium that shine like bright sparks on the scan and cast small shadows behind them. That calcium is close to a signature: a mass full of bright calcified spots in a young child is a retinoblastoma until proven otherwise. The handheld scan catches it on an eye that a frightened toddler will not hold open for any other look. A white glow in the pupil, caught in a family photograph, is often what first brings a child in. The scan then confirms a solid calcified mass behind it. Found early, a retinoblastoma is one of the cancers of childhood most often cured.

These patterns name a growth more often than not. They do not replace the eye specialist who confirms the diagnosis. What the scan does is sort a mass into the likely group, fast, on the first visit. A dome with a quiet inside goes down the melanoma path with its urgency. A flat freckle goes onto a watch list. A lumpy bright mass in someone with cancer sends the search back to the body. The scan turns an unknown growth into a working answer. None of this is the final diagnosis. It is a strong first guess, made in minutes, on a child or an adult who may not sit still for anything longer. The guess sets the speed and the direction of everything that comes next.

The one number that matters

Growth is what separates a dangerous tumor from a harmless one. Growth is also a number the scan gives better than any other test. The height of a mass, measured from the wall to its peak, is written down to a tenth of a millimetre and dated. A freckle holds the same height a year later. Gaining even a millimetre of height changes everything: the lesion has declared itself, crossing from a thing to watch into a thing to treat. The same probe, the same measurement, repeated over months, is what catches that change. A single scan names a likely tumor. A run of scans proves whether it grows. That one number, followed from visit to visit, decides more cases than any single feature seen on any single day. The smallest growth worth tracking is about half a millimetre, a change finer than a clinician’s eye can judge. The calipers catch it. Each measurement is taken the same way, through the thickest part of the mass, so one visit can be set against the next. A photograph of the screen goes into the file beside the number.

What sits around the mass

A tumor rarely sits alone. What surrounds it adds to the picture. The retinal detachment a tumor lifts can spread far beyond the mass itself, a wide curtain of lifted retina the scan traces back to the growth that caused it. Fluid pooling under that retina shifts when the head tips. That shift is the mark of loose serous fluid. The scan follows the detachment down to the mound it springs from, joining the effect to its cause. The pattern of the detachment is a clue by itself. A solid tumor lifts the retina in a smooth, broad sweep from its edge. The scan measures how far that lifted retina reaches and notes it beside the size of the mass.

Blood flow inside a tumor is another clue. A living growth carries its own vessels. On a scan with colour Doppler those vessels light up with flow inside the mass. A melanoma and a hemangioma both run their own blood. Watching the mass for that internal flow, and for the fine pulsation of vessels within it, separates a true growing tumor from a lump of dead tissue that only looks like one. The handheld shows the life inside the mound along with its shape. Colour Doppler paints moving blood over the grey picture, so a vessel inside the mass shows up as a patch of colour. A melanoma often carries a rich, fine network of vessels inside it. That flow, read together with the shape and the inner shade, builds the fullest picture a scan can give of a growth.

Watching, and knowing when to refer

Most small pigmented spots in the eye are harmless freckles. Most of them never need more than a watchful eye. That watching is exactly what the handheld does best. A small flat lesion is scanned, measured, and photographed, then scanned again in a few months to see whether it has moved. A lesion that holds its size is left alone and checked now and then. A lesion that thickens, or grows fluid beneath it, or starts to show the quiet hollow inside of a melanoma, is sent on without delay. The scan turns a vague worry into a clear schedule of looking. A pigmented spot with no thickness and no fluid is a freckle until something changes. The risk signs are written into a short checklist used the world over: thickness over two millimetres, fluid under the retina, orange pigment on the surface, symptoms, and a margin near the optic disc. The more of those a spot shows, the shorter the leash it is kept on.

The referral itself is to an eye cancer service, where the diagnosis is settled and the treatment chosen. A suspected ocular melanoma is seen by an ocular oncologist within days. The scan gives that service a head start: a size, a shape, an internal reading, a record of any growth already seen. The specialist confirms the tumor with their own detailed scans and exam. From there the path runs to the treatments that save the eye or the life, radiation plaque, laser, or surgery, the choice set by the kind and the size of the growth. A radiation plaque, sewn over the tumor for a few days, treats many medium melanomas. Laser handles some smaller ones. The largest growths, and eyes already lost to the tumor, may need removing to save the life. The scan’s measurements help point to the right path before the patient is ever seen.

The scan stops short of the final word. It cannot read the genetics that say how a melanoma will behave, nor grade a tumor the way a pathologist does. It names a likely kind and a size. A likelihood is not a certainty. A small or flat lesion can read as harmless and still need the specialist’s closer eye. The handheld is the first look and the running watch. The last word belongs elsewhere. It is honest about that line. That line is where the eye cancer service takes over. The genetics are read from a sample of the tumor itself, taken at the time of treatment. They sort a melanoma into the kind that rarely spreads and the kind that often does. No scan can see that from the outside. The handheld knows the edge of what it can do.

The numbers it gives are real all the same. A height to a tenth of a millimetre, a base across the wall, an internal reflectivity high or low, a detachment measured at its edge: these are the facts a plan is built on. The handheld gathers them at the chair in a few minutes, on an eye no other look can get into. The gathering is its whole job. It does it as well as a machine many times its size. A base and a height to a fraction of a millimetre is more than a guess. It is a measurement another clinician can repeat and check. The internal reflectivity, high or low, is a measured fact about the tissue. These are the things that make the scan worth trusting.

Where the handheld fits

A handheld scanner puts this picture of a tumor into a small box at the bedside or the clinic chair. The probe is the same one used for the rest of the eye, run gently over a closed lid. It measures a mass, shows its inside, traces the detachment it has caused, and dates the lot for the next visit. A clinic with no large ultrasound machine, or a patient who cannot travel to one, still gets the size and the character of a growth shown on the spot. Nothing has to leave the room for the first answer. The whole machine weighs less than a textbook and runs off a tablet or a phone. It travels to a bedridden patient, to a clinic in a small town, to a children’s ward the big scanner cannot reach. The eye is scanned where the patient already is.

What it asks in return is a careful hand and a careful eye. The A-scan trace that separates a melanoma from a freckle takes practice to take well and to trust. A reflectivity taken off a poorly aimed line means little. The examiner lines the sound through the centre of the mass, holds it steady, and reads the spikes against what a melanoma, a metastasis, and a hemangioma each look like. The machine reports a height and a row of spikes. Knowing what they mean is the examiner’s own skill. The work rewards an examiner who has built a memory of many tumors. A melanoma seen a hundred times is known on sight. The first few are studied slowly, against a chart, with a senior eye nearby. The skill comes from the count of eyes seen.

So a growth at the back of an eye, hidden from the light or plain to see, becomes a measured, named, dated thing under the handheld probe. The scan finds the mass, reads its shape and its quiet or busy inside, follows the retina it has lifted, and writes down the height that the next scan will be measured against. From that the eye cancer service takes a running start. The small machine on the closed lid is where the watch on a tumor begins, and where, visit after visit, it is kept. What began as a frightening shadow at the back of an eye ends as a line in a chart, a height and a date the next visit will answer to. The patient keeps the eye, or the eye keeps the patient alive, on the strength of a growth caught small.

Common questions about ultrasound for an intraocular tumor

How does an intraocular tumor look on ultrasound?

As a solid mass, a mound of tissue rising off the inner wall of the eye into the dark vitreous. It has body and thickness, a filled shape all the way through. Many tumors rise as a smooth dome. A choroidal melanoma can grow into a mushroom or collar-button shape. The scan measures how wide the mass sits on the wall and how high it stands off it.

Can ultrasound tell a dangerous tumor from a harmless one?

It gives strong clues. A choroidal melanoma tends to be a tall dome or mushroom with a quiet, hollow inside on the A-scan, called low internal reflectivity. A harmless freckle is small, a thin flat patch. A spread cancer is often lumpy with a bright, busy inside, sometimes in both eyes. A childhood retinoblastoma is full of bright flecks of calcium. The patterns name a likely kind, which the eye cancer service then confirms.

What is the single most useful thing the scan measures?

The height of the mass, from the wall to its peak, written to a tenth of a millimetre. Growth from one visit to the next is what marks a dangerous tumor. A lesion that holds the same height for a year is reassuring. One that has gained a millimetre has declared itself. The same probe and the same measurement, repeated over months, is what catches that change.

Why use ultrasound rather than just looking in the eye?

Because a tumor can hide behind a bleed or a cataract that blocks the view, and because the scan reads things a look cannot. It measures the mass to a fraction of a millimetre, reads the kind of tissue inside it from the A-scan, and traces the retinal detachment around it. It does all of this without harm, again and again, on a schedule of watching.

Does the scan replace the eye cancer specialist?

No. The handheld gives the first read and the running watch: a size, a shape, an internal reading, a record of any growth. It cannot read the genetics of a melanoma or settle the diagnosis on its own. A suspected tumor goes to an ocular oncology service, which confirms it with detailed scans and chooses the treatment. The scan is where the watch begins. Where it ends is with the specialist.

About the Author

Julien Mercier

Senior R&D Engineer · Medical Ultrasound Transducer Development

Senior R&D Engineer with an M.S. in Applied Physics and over 15 years of experience in medical ultrasound transducer development, specializing in the design verification and performance testing of high-frequency imaging transducers. Currently leading the development and verification of the company’s next-generation high-frequency linear-array transducer, responsible for imaging performance evaluation and reliability analysis in preclinical testing. Brings extensive hands-on experience in piezoelectric element tuning, beamforming parameter optimization, and system-level performance testing.